cyrilzakka/clinical-trials huggingface dataset:
Anti-cancer DC Cell Vaccination to Treat Solid Tumors

Placental or tumor-derived heat shock protein gp96 is collected, purified, and stored. The DC cells are isolated from the patient's blood and then cocultured with the gp96 to obtain the activated DC cell product. The manufactured DC cells are subcutaneously or intra-tumor injected into the patient. Clinical studies will be performed to test anti-cancer function of the DC vaccination for immunotherapy of cancer patients. In this phase I study, the safety, tolerance, and preliminary efficacy of the DC vaccine immunotherapy on advanced cancers will firstly be evaluated.

1. Choose appropriate patients with advanced solid cancers, with written consent for this study;
2. Perform biopsy to get fresh sample for generation gp96 protein; Collect DC cells from the cancer patient;
3. Produce appropriate DC cell vaccine and deliver the vaccine into selected patients via local injections, and follow up closely to collect related results as required;
4. To enhance the killing capability, cotreatment the patients with vaccine aduvants or PD1/PDL1/CTLA4 antibodies may be applied;
5. Evaluate the clinical results as needed.

Eligibility Criteria:
Inclusion Criteria:

1. Patients with advanced cancer; 2. Life expectancy \>12 weeks; 3. Adequate heart, lung, liver, kidney, and blood function; 4. Available high quality vaccine for human use; 5. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.

-

Exclusion Criteria:

1. Had accepted gene therapy before;
2. Severe virus infection such as HBV, HCV, HIV, et al;
3. Known HIV positivity;
4. Active infectious disease related to bacteria, virus,fungi,et al;
5. Other severe diseases that the investigators consider not appropriate;
6. Pregnant or lactating women;
7. Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day);
8. Other conditions that the investigators consider not appropriate.
The Relationship of Hemoglobin A1c and Diabetic Wound Healing

The purpose of this study is to investigate the relationship of hemoglobin A1c in diabetic wound healing. Additionally, a comparison of two wound dressings, AmeriGel® (Amerx Health Care Corp., Clearwater, FL) and Bacitracin, with and without vitamin C supplementation, will be done to evaluate impact on time to wound closure.

This is a prospective randomized controlled study evaluating the relationship of hemoglobin A1c in diabetic wound healing. Length of time for wound closure will be compared using four treatment options.

Eligibility Criteria:
Inclusion Criteria:

* \>18 years of age
* Diabetic (Type I and Type II)
* Ulceration of the foot at least one centimeter in width/length
* Ulceration at least 0.2 centimeters in depth

Exclusion Criteria:

* Ulceration width/length \> 7.5 centimeters
* Wound depth \> 1.25 centimeters
* Purulent, excessive drainage and/or other signs of infection (i.e. erythema, edema, warmth)
* Inability to provide informed consent
* Inability to swallow pills (vitamin C supplement)
* Patients with concurrent renal problems
* Patients with medication contraindications to Vitamin C and/or topical wound dressings
Effect of Krill Oil on Cognitive Function in Adults

The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Krill oil on cognitive function in adults with subjective memory impairment for 12 weeks.

Previous animal studies have indicated that Krill oil may have the ability to improve cognitive function. Therefore, the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Krill oil on cognitive function in adults with subjective memory impairment for 12 weeks; the safety of the compound are also evaluate. The Investigators examine chemical and metabolic parameters, and cognitive function at baseline, as well as after 6 and 12 weeks of intervention. One hundred adults were administered either 500 mg of Krill oil or a placebo each day for 12 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Global Deterioration Scale (GDS) 2 or 3

Exclusion Criteria:

* Abnormal liver or renal function (i.e., serum aminotransferase activity \> 3 times of upper limit of reference range and serum creatinine concentrations \> 1.2 mg/dL)
* Diabetes (diagnosed clinically or fasting glucose level \> 126 mg/dL)
* History of viral hepatitis or cancer
* Uncontrolled hypertension
* History of serious cardiac disease such as angina or myocardial infarction
* History of gastrectomy
* History of medication for psychiatric disease
* Administration of oriental medicine including herbs within the past 4 weeks
Relaxation Interventions for Pre-term Mothers on Hospitalized Bed-Rest

The purpose of this study is to investigate the effects of participation in relaxation exercises on pregnant women who are hospitalized on bed-rest.

Women, 18 or older, who consent to this study will participate in a preliminary interview. Study participants will then be trained in the use of progressive muscle relaxation and guided imagery for pregnancy. Participants will be issued a listening device and an audio file and asked to practice it on a daily basis while in the hospital.

Prior to discharge or delivery, the participant will be visited by a member of the research team who will conduct a follow-up interview. The interviews and the relaxation practice sessions will take between 30 and 45 minutes each. The interviews will be audio-recorded, although no identifying information about the participants will be recorded.

At the conclusion of the study, participants will be given a CD of the audio relaxation program and thanked for their participation in the study.

There is minimal risk anticipated in association with participation in this study. All information gained from this study will remain confidential and is for educational purposes only. Participants are entitled to terminate their participation in the study at any time.

It is hoped that the results of this study will provide information about an intervention that may be beneficial to women with high-risk pregnancies. It is also hoped that participation in the exercises will be enjoyable and/or beneficial to you in some way. The results of this study may be used to justify further studies or to influence the type of interventions offered in this or similar settings.

All data collected from the research will remain confidential. Data collected from participants will immediately be assigned an identification number so that no one will be able to identify any individuals in the study.

Eligibility Criteria:
Inclusion Criteria:

* Pregnant women on bed rest for high risk pregnancy

Exclusion Criteria:

* none
Short Implants in Edentulous Mandible

Main aim of this study was to assess survival rates of short implants with a length of 4 mm in the edentulous mandible after 1, 3, and 5 years.

It is hypothesized that survival rates after 1, 3, and 5 years of Straumann Roxolid® / SLActive® 4 mm short implants do not differ from values of Straumann SLActive implants with more than 4 mm length in the same clinical situation.

Eligibility Criteria:
Inclusion Criteria:

General criteria:

* Age: 18 to 70
* Edentulous mandible with reduced bone level in the posterior region (\> 5 mm and \< 8 mm above nerve conduit)
* Physical and mental condition that allow surgery and a 5-year follow-up period to be carried out without foreseeable problems
* Obtained informed consent from the patient

Specific criteria:

* Limited vertical space for implant placement, where conventional implants with lengths of more than 4 mm cannot be used
* Tooth loss or extraction at least 8 weeks before implant surgery
* Healthy implantation site
* Favorable and stable occlusal relationship
* Complete denture in the mandible. If no denture available, an interims prosthesis will be fitted
* Natural full dentition or sufficient complete or partial dentures in the maxilla

Exclusion Criteria:

General criteria:

* Any conditions or circumstances which would interfere with the requirements for oral surgery
* Allergy to any metallic implant component
* Acute, untreated periodontitis
* Previous oro-maxillo-facial radiotherapy
* Any disorders in the planned implant area such as previous tumors or chronic bone disease (e.g., rheumatoid disease)
* Any ongoing application of interfering medication (steroid therapy, bisphosphonate, etc.)
* Alcohol or drug abuse
* Heavy smoking (\>10 cigarettes/day)
* Uncontrolled diabetes
* Severe bruxism or other destructive oral habits
* Pregnant or lactating women

Specific criteria:

* Need for a major bone regeneration technique
* Infections in adjacent tissue of the planned implantation site.
* Bleeding on probing (BOP) and plaque index (PI) higher 25%
* Insufficient bone volume in the posterior region for placing a Straumann Roxolid® / SLActive® 4mm short implant and in the interforaminal region for placing a Straumann Roxolid® / SLActive® implant with a minimum length of 10 mm determined by radiographic analysis (OPG)
Social Worker in an Eye-Care Service

The purpose of this research study is to determine whether involvement with a social worker helps reduce distress, depression, and increase patient activation in participants over a 6 month intervention period. The study will also describe common barriers to care that participants face.

An appointment will be scheduled for participant to meet with a social worker. The appointment may happen on day of participant's scheduled clinic appointment or on another mutually decided upon date and time. Should participant choose to participate, this first visit will be Visit 1 for the study.

Visit 1: Baseline

Informed consent will be obtained demonstrating an interest in participating.

A visit with the social worker will take place during Visit 1. This session will be held in a private office and allows participant time for discussion regarding any challenges, struggles and/or barriers they may be experiencing.

The following baseline questionnaires/surveys will be administered:

Modified Patient Activation Measure - measures participant confidence in taking care of their own health.

Distress Thermometer - measures participant distress level during the past week.

Patient Health Questionnaire -measures depression symptoms and severity if any.

Clinical information will be taken from participant's medical record. There may be follow-up questions related to data if information is unclear or incomplete.

Upon completion of Visit 1, participant will receive a satisfaction survey to evaluate how participant satisfaction with social worker interaction.

Social Worker Interventions: After Visit 1 and before Visit 2

The social worker will develop an intervention for participant during Visit 1 appointment. As many calls or in person meetings participant requires will take place. There will be no limit and it will be determined by participant's needs.

Visit 2: Follow-up After 6 Months

Upon completion of participant's six month follow-up in the study, the following questionnaires/surveys will be administered:

Modified Patient Activation Measure - measures how confident participant is at taking care of their own health.

Distress Thermometer - measures how much distress participant has been experiencing in the past week.

Patient Health Questionnaire - measures if participant has symptoms of depression and the severity of those symptoms.

Satisfaction Survey - measures how satisfied participant is with the social worker interaction.

Eligibility Criteria:
Inclusion Criteria:

* Patients seen at Wills Eye Hospital in the Glaucoma Service
* Glaucoma of any type, characterized by glaucomatous optic neuropathy and corresponding visual field (VF) defect
* Referred to staff social worker for intervention
* Ability to read, write, speak and understand English

Exclusion Criteria:

* None
Does Induction Dosage in Latent Phase Affect Active Phase of Labor?

This study evaluates the need of oxytocin therapy in active phase of labor. there will be two groups treating with oxytocin in latent phase.One group will be treated with low dose oxytocin therapy and the other group will be treated with high dose oxytocin therapy. oxytocin treatment will be ceased at the beginning of the active phase of labor. the need of oxytocin treatment in active phase of labor will be compared between two groups.

Oxytocin treatment in active phase of labour is used with respect to clinicians preference and best approach has not been described. We want to investigate the effect of oxytocin treatment by using different regims in latent phase of labor when oxytocin treatment is ceased in active phase of labour. In our trial we discontinued oxytocin in active phase of labour and investigate which group needs oxytocin therapy due to inadequate uterine contractions and arrest of labor.

Eligibility Criteria:
Inclusion Criteria:

* Live fetus in cephalic presentation, sonographically estimated fetal weight less than 4200 g, undergoing induction of labor at 37-42 weeks of gestation, having indications of labor, no previous uterine surgery

Exclusion Criteria:

* malpresentation, placenta previa, previous uterine surgery, multiple gestation, active genital herpes, non-reassuring fetal heart rate pattern
Stroke-induced Immunodepression in Neurorehabilitation

The close interconnection between nervous system and the immune system is well known. Brain injuries lead to homeostasis disruption. On the one hand they result in increased brain inflammation contributing to tissue repair, at the expense of a possible extension of tissue damage. On the other hand, they lead to systemic down-regulation of innate and adaptive immunity, determining higher vulnerability to infections, responsible of death and comorbidities in the acute and subacute setting.

Aim of the study was to evaluate the role of immunosuppression in the neurorehabilitation pathway in patients with stroke.

The perfect balance between nervous and immune system could be severely impaired after brain injuries, such as strokes.

In the acute phase, inflammatory mediators are responsible of central nervous system inflammation, associated to tissue repair at the expense of possible secondary brain injury or damage expansions.

In the mean time, activation of hypothalamic-pituitary-adrenal axis and the autonomic nervous system determine downregulation of innate and adaptive immunity, with decreased circulating T cell count and reduced lymphocytic response. The degree of these changes is linked to the severity of brain damage and inevitably lead to higher vulnerability to infections, representing a negative prognostic factor in the acute phase.

Association between immunosuppression and functional outcome in the neurorehabilitation setting are missing.

Aim of this study was to evaluate the role of immunosuppression in the neurorehabilitation journey in patients with stroke.

We analyzed the neutrophil-to-lymphocyte ratio, a useful tool to investigate alterations in both the innate and adaptive immune systems. We correlated it to clinical and neurorehabilitation scales, investigating disability, functional status, as well as gait analysis and occurrence of infectious complications. All outcomes were measured on admission in Neurorehabilitation setting and at hospital discharge.

Eligibility Criteria:
Inclusion Criteria:

* diagnosis of first episode of ischemic stroke or primary spontaneous intracerebral haemorrhage (both confirmed by proper neuroimaging)
* admission to the Neurorehabilitation ward within 30 days from the index event

Exclusion Criteria:

* medical history of immunodeficiency or immunoproliferative disease
* immunosuppressive or immunomodulating therapy in the year before the index event
* systemic steroids in the six months before the index event
* Glasgow Coma Scale \< 8 at hospital admission
* other diagnosis of neurological diseases
* missing clinical/demographic data
Virtual Reality Rehabilitation for Stroke Patients in the Hospital and At Home.

The goal of this clinical trial is to test whether a low-cost virtual reality (VR) motor rehabilitation platform can improve motor recovery in people recovering from a first-time ischemic stroke both in the hospital and at home. The study focuses on adults aged 18 and older who have experienced moderate to severe upper limb motor deficits.

The main questions it aims to answer are:

* Can VR-based motor therapy improve upper limb motor function compared to standard care?
* Is VR-based motor therapy a feasible and acceptable treatment option for stroke patients?

Researchers will compare patients receiving VR therapy to those receiving standard care to see if the VR therapy leads to greater improvements in motor recovery and more positive patient experiences.

Participants will:

* Complete standardized assessments of motor function and quality of life at multiple time points.
* Participate in VR therapy sessions (if in the treatment group), using gamified activities designed to improve upper limb movement.
* Provide feedback on their experience with the VR system, including ease of use, motion sickness, and engagement.

This study will help determine whether VR-based rehabilitation can be a practical, effective way to improve access to therapy and recovery outcomes for stroke patients, especially in rural settings with limited rehabilitation resources.


Eligibility Criteria:
Inclusion Criteria:

* clinical diagnosis of first-time ischemic stroke involving the middle cerebral artery, confirmed by CT or MRI;
* score between 6 and 40 on Fugl-Meyer Assessment's Upper Limb Extremity Subscore (FM - UE), indicating moderate to severe motor deficit;
* ability and willingness to provide consent (score of 18 or more on the Montreal Cognitive Assessment) or assent (for scores lower than 18 on MoCA with consent provided by an authorized third party with the necessary legal authority to consent on behalf of patient)
* INPATIENT ARM: less than 5 weeks since stroke onset with admission to Valley Regional Hospital in Kentville, NS, Canada
* OUTPATIENT ARM: less than 3 months since stroke onset with discharge to home setting located within 1 hour drive of Valley Regional Hospital in Kentville, NS, Canada

Exclusion Criteria:

* brainstem, cerebellar or bilateral stroke lesion
* a secondary neurological condition (e.g., Parkinson's disease)
* musculoskeletal injuries interfering with task performance
* an uncorrected visual deficit due to stroke or other etiologies
* apraxia as identified by clinical assessment
Confocal Laser Endomicroscopy Based Diet in Functional Dyspepsia

After a thorough baseline evaluation, functional dyspepsia (FD) patients will be exposed to nutrients while undergoing confocal laser endomicroscopy (CLE). Patients presenting an acute mucosal reaction upon nutrient exposure will be instructed to exclude their respective trigger nutrient or a nutrient without mucosal reaction (=sham diet) from their diet for 4 weeks in a randomized, blinded crossover fashion.

The aim of the trial is to assess the symptomatic response to the targeted diet and further elucidate mechanisms underlying the acute mucosal reactions observed in CLE upon nutrient exposure.


Eligibility Criteria:
Inclusion Criteria:

* Age 18-70 y/o (70 years included)
* Male or female subjects
* FD (PDS, EPS or overlap) according to Rome IV criteria
* Provide written informed consent to participate in the study
* Women of child-bearing potential agree to apply a highly effective method of birth control during the entire duration of the trial. Highly effective birth control is defined as those which result in a low failure rate (i.e., less than 1% per year) when used constantly and correctly such as implants, injectables, combined oral contraceptive method, or some intrauterine devices (IUDs), sexual abstinence, or vasectomized partner. Women of non-childbearing potential may be included if surgically sterile (tubal ligation or hysterectomy) or postmenopausal with at least 2 year without spontaneous menses.
* Subjects who are capable to understand the study and the questionnaires, and to comply with the study requirements.

Exclusion Criteria:

* Pregnant or breastfeeding women
* History of major surgery of the gastrointestinal tract (cholecystectomy and uncomplicated appendectomy are allowed)
* Symptoms predominantly associated with irritable bowel syndrome or gastro-esophageal reflux disease
* IgE-mediated food allergies identified by immunocaps blood tests
* Known underlying organic gastrointestinal disease
* Current use of NSAIDs, proton-pump inhibitors, systemic histamine-receptor antagonists, mast cell stabilizers, corticosteroids, opioids (need to be stopped at least 2 weeks). Use of antibiotics in the past 6 weeks.
* Allergy to Fluorescein or Propofol
* Known celiac disease
* Following a diet, interfering with the study diet in opinion to the investigators
The Effect of Zolpidem on Outcomes Following Lumbar Spine Fusion

The purpose of this study is to evaluate if peri-operative zolpidem for posterior lumbar spinal fusion improves patient reported outcomes following surgery.

Patients who are undergoing one- to three-level spinal fusion for degenerative lumbar disease will be recruited. They will be randomized to either receive zolpidem or placebo two days preoperatively and five days postoperatively.

Eligibility Criteria:
Inclusion Criteria:

* degenerative lumbar disease
* age of 18-75
* undergoing open primary one- to three-level lumbar fusion

Exclusion Criteria:

* currently use a sleep aid nightly
* diagnosed with insomnia or sleep apnea
* history of delirium with opiates or zolpidem
* allergic to opiates or zolpidem
* had previous lumbar spine surgery
* undergoing minimally invasive lumbar fusion,
* undergoing lumbar fusion for fracture, infection, tumor, or an inflammatory spondyloarthropathy
Comparison of Low and Normal Flow Anesthesia in Robotic Assisted Radical Prostatectomy

Robot-assisted laparoscopic radical prostatectomy has gained increasing popularity compared to open radical prostatectomy with its advantages such as low blood loss, reduced blood transfusion rate, low complication rate, and shortened hospital stay. Since robot-assisted laparoscopic radical prostatectomy should be performed in the limited retroperitoneal area, insufflation of the abdomen with carbon dioxide (CO2) (pneumoperitoneum) and steep Trendelenburg position are required to provide better surgical vision.

Low-flow anesthesia warms and moistens the inhaled gases, creating a more physiological breathing atmosphere during anesthesia. In addition, it provides cost advantage by reducing inhalation agent consumption and reduces atmospheric pollution. Studies show that long-term minimal flow anesthesia is safe and advantageous for non-laparoscopic surgery.

The aim of this study is to compare low-flow (1L/min) with normal flow (3lt/min) desflurane anesthesia in terms of hemodynamic and respiratory parameters, inhalation agent consumption and soda lime consumption for robotic assisted laparoscopic radical prostatectomy surgery.

The secondary aim of the study is to compare the effects of low-flow and normal-flow anesthesia in the steep trendelenburg position (45°) used for robotically assisted laparoscopic radical prostatectomy.


Eligibility Criteria:
Inclusion Criteria:

- ASA I-II risk group

Exclusion Criteria:

* ASA III, IV, V,
* concomitant serious cardiac, respiratory, hepatic, renal disturbance,
* mental status disorder and hearing problem,
* anxiety and depression and/or other psychiatric disorders,
* patient's refusal